An Exploratory Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients with Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy
NCT #
NCT04739293
Condition(s)
Solid Tumor
Molecular Target(s)
ARK5, CDK4/6, NUAK1 protein
Drug Classification(s)
Small Molecule
Agents(s)
ON 123300
Phase(s)
I
Mechanism of Action
ON 123300 is a small molecule, dual inhibitor of CDK4/6 and ARK5, a key enzyme controlling cellular energy homeostasis. Inhibition of ARK5 by ON 123300 collapses oncogene-altered energy metabolism, leading to programmed cell death.
Purpose
- About the safety and tolerability of the study drug
- If the study drug prevents or delays tumor growth or shrinks existing tumors
- How much of the study drug is absorbed into the blood and how fast it is removed
- How the study drug is acting in your body
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.